NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...
Although Denso is no longer in a net cash position, in fiscal 2023 net debt/EBITDA remained low at 0.2. Since 2012, the company has been able to self-fund its investments through its cash flow from ...
Behind them, Marcus Smith, who last started a Test for England at full-back in the 2023 World Cup play-off victory over Argentina, is set to wear the 15 jersey to counteract France’s long kicking game ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...